FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to application of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol in free form or in form of pharmaceutically acceptable salt (FTY720) for treatment of autoimmune disease of disorder, where dose of FTY720 during initial period of 4 days constitutes 0.5 mg/1 mg/1.5mg/2 mg, respectively, where after that treatment is continued with day dose equal 0.5 mg.
EFFECT: invention relates to set, containing day units of drug forms of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol in free form or in form of pharmaceutically acceptable salt (FTY720) for treatment of autoimmune disease of disorder.
5 cl
| Title | Year | Author | Number |
|---|---|---|---|
| MODULATORS OF RECEPTOR S1P FOR TREATMENT OF MULTIPLE SCLEROSIS | 2007 |
|
RU2569732C9 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING S1P RECEPTOR MODULATOR | 2007 |
|
RU2487703C2 |
| S1P RECEPTOR MODULATORS FOR MULTIPLE SCLEROSIS TREATMENT | 2007 |
|
RU2617502C2 |
| SIP RECEPTOR MODULATORS FOR TREATING MULTIPLE SCLEROSIS | 2007 |
|
RU2495664C2 |
| COMBINATIONS WHICH INCLUDE RECEPTOR S1P AGONIST AND JAK3 KINASE INHIBITOR | 2005 |
|
RU2415678C2 |
| APPLICATION OF SPHINGOSINE-1-PHOSPHATE (SIP) RECEPTOR AGONISTS FOR TREATMENT OF DEGENERATIVE BRAIN DISEASES | 2004 |
|
RU2379030C2 |
| ORAL PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2475237C2 |
| COMPOSITIONS CONTAINING MODULATORS OF SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR | 2008 |
|
RU2779056C2 |
| LIQUID FORMULATIONS | 2006 |
|
RU2470631C2 |
| LIQUID COMPOSITIONS | 2006 |
|
RU2428180C2 |
